{"id":20041,"date":"2021-12-20T10:45:55","date_gmt":"2021-12-20T09:45:55","guid":{"rendered":"https:\/\/idibell.cat\/?p=20041"},"modified":"2021-12-20T10:45:55","modified_gmt":"2021-12-20T09:45:55","slug":"descobreixen-una-nova-via-de-regulacio-genetica-associada-amb-lobesitat","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/12\/descobreixen-una-nova-via-de-regulacio-genetica-associada-amb-lobesitat\/","title":{"rendered":"Descobreixen una nova via de regulaci\u00f3 gen\u00e8tica associada amb l\u2019obesitat"},"content":{"rendered":"<p>Investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (<a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-ginecologic\/\">IDIBELL<\/a>), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona (<a href=\"https:\/\/idibgi.org\/\">IDIBGI<\/a>) i la Facultat de Medicina i Ci\u00e8ncies de la Salut de Universitat de Barcelona (<a href=\"https:\/\/www.ub.edu\/web\/portal\/ca\/\">UB<\/a>) han descobert un <strong>nou mecanisme implicat en el desenvolupament de l\u2019obesitat<\/strong>. El treball descriu que la reducci\u00f3 de l&#8217;expressi\u00f3 d&#8217;un grup de microARNs, petites mol\u00e8cules que regulen l&#8217;expressi\u00f3 de gens concrets, provoca un increment en l\u2019expressi\u00f3 del gen de la sinucle\u00efna gamma (SNCG) que acaba per promoure l\u2019expansi\u00f3 dels dep\u00f2sits de greix.<\/p>\n<p>En el treball publicat a la revista <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/advs.202104759\"><strong><em>Advanced Science<\/em><\/strong><\/a> es mostra que <strong>els ratolins que no expressen el grup de microARNs presenten una gran expansi\u00f3 del teixit gras<\/strong>, tal com demostren els estudis de resson\u00e0ncia magn\u00e8tica i una acurada caracteritzaci\u00f3 fenot\u00edpica en ratolins mascles i femelles. Pel que fa als humans, els autors indiquen que aquelles persones amb obesitat tenen una menor expressi\u00f3 del microARNs, disminuci\u00f3 que es reverteix quan els mateixos individus perden pes.<\/p>\n<p>\u201c<em>Aquesta reversi\u00f3 en l\u2019expressi\u00f3 del microARNs quan es perd el pes ens indica que es tracta d\u2019una via din\u00e0mica i reversible, i que per tant, podr\u00edem aprendre en un futur a modular-la com a nova via de tractament contra l\u2019obesitat<\/em>\u201d, apunta de la <strong>Dra. Ruth Rodr\u00edguez-Barrueco<\/strong>, investigadora principal a l\u2019IDIBELL i la Universitat de Barcelona i primera autora del treball.<\/p>\n<p>&nbsp;<\/p>\n<h3>Ampliant el coneixement del paper dels adip\u00f2cits en l\u2019obesitat<\/h3>\n<p>Els adip\u00f2cits s\u00f3n c\u00e8l\u00b7lules molt especialitzades que emmagatzemen energia en forma de gotes lip\u00eddiques. <strong>Les persones amb obesitat tenen un nombre superior d\u2019adip\u00f2cits als seus dip\u00f2sits de greix<\/strong>, caracter\u00edstica que es defineix abans d\u2019arribar a la vida adulta. Una mala gesti\u00f3 d\u2019aquests magatzems de greix i la renovaci\u00f3 i vida \u00fatil d\u2019aquestes c\u00e8l\u00b7lules pot comportar un augment de pes i les complicacions t\u00edpicament vinculades a l\u2019obesitat. En aquest sentit, l\u2019augment del teixit gras observat durant el decurs d\u2019aquesta recerca \u00e9s degut tant a l\u2019augment del nombre com a l\u2019engrandiment dels adip\u00f2cits que formen part integrant dels dip\u00f2sits de greix. L\u2019estudi liderat per l&#8217;IDIBGI i l&#8217;IDIBELL aprofundeix en el coneixement d\u2019aquest camp i demostra que aquest grup de microARNs, anomenat <strong>miR-424(322)\/503<\/strong>, funciona com <strong>un sistema de control de l\u2019acumulaci\u00f3 desproporcionada de greix corporal<\/strong>.<\/p>\n<p>\u201c<em>Aquest estudi, fruit d\u2019una serendipitat, representa un pas decidit envers la caracteritzaci\u00f3 d\u2019aquests microARNs i tot el que poden oferir com a criteri diagn\u00f2stic i dianes terap\u00e8utiques; amb tota la ci\u00e8ncia del tub d&#8217;assaig, per\u00f2 sense perdre de vista la realitat cl\u00ednica del pacient ob\u00e8s<\/em>\u201d, afirma per la seva banda el <strong>Dr. Francisco Jos\u00e9 Ortega<\/strong>, investigador principal de l\u2019IDIBGI i del CIBER de la fisiologia Fisiopatologia de l\u2019Obesitat i la Nutrici\u00f3 (CIBEROBN).<\/p>\n<p>&nbsp;<\/p>\n<h3>Uns microARNs supressors de tumors que tamb\u00e9 han resultat ser supressors de l\u2019obesitat<\/h3>\n<p>Fins ara, la Dra. Ruth Rodr\u00edguez-Barrueco i el Dr. David Llobet-Navas, investigador principal de l\u2019IDIBELL i del Centre d\u2019Investigaci\u00f3 en Xarxa d\u2019Oncologia (CIBERONC), havien centrat els seus estudis el grup miR-424(322)\/503 en la capacitat d\u2019inhibir el creixement tumoral en c\u00e0ncer de mama.<\/p>\n<p>\u201c<em>En aquest estudi no nom\u00e9s hem vist que el grup de microARNs amb el que est\u00e0vem treballant fins ara regulava l\u2019expressi\u00f3 d\u2019un conegut oncogen com \u00e9s la l\u2019SNCG, sin\u00f3 que a m\u00e9s hem descobert la relaci\u00f3 d\u2019aquets amb l\u2019obesitat. <strong>Aquesta coincid\u00e8ncia apunta clarament a una connexi\u00f3 potencial entre l\u2019obesitat i la incid\u00e8ncia del c\u00e0ncer de mama<\/strong><\/em>\u201d, indica el <strong>Dr. David Llobet-Navas<\/strong>, autor de correspond\u00e8ncia de l\u2019estudi.<\/p>\n<p>Aquest treball finan\u00e7at per la Fundaci\u00f3 de la Marat\u00f3 de TV3 l\u2019any 2016 ha estat fruit d\u2019una estreta col\u00b7laboraci\u00f3 entre dos centres de recerca: l\u2019IDIBELL i l\u2019IDIBGI, liderat pel Dr. Francisco Jos\u00e9 Ortega, investigador principal de l\u2019IDIBGI, que \u00e9s l\u2019institut que ha coordinat aquest projecte. A m\u00e9s, es tracta d\u2019un estudi en que dos programes troncals del Centre d\u2019Investigaci\u00f3 Biom\u00e8dica en Xarxa (CIBER) uneixen\u00a0 forces per assolir una fita comuna: el CIBERONC i el CIBEROBN.<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Els resultats de l\u2019estudi, publicat a la revista Advanced Science, mostren que una reducci\u00f3 de l&#8217;expressi\u00f3 del grup de microARNs en el teixit gras provoca un augment en el nombre de les c\u00e8l\u00b7lules que emmagatzemen greixos i el creixement hipertr\u00f2fic de les mateixes.<\/p>\n","protected":false},"author":8,"featured_media":20042,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,365,447],"tags":[],"class_list":["post-20041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-ginecologic","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-01-03 02:32:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=20041"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20041\/revisions"}],"predecessor-version":[{"id":20043,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20041\/revisions\/20043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20042"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=20041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=20041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=20041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}